Joshua A Hill
Overview
Explore the profile of Joshua A Hill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
3388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kinoshita H, Walti C, Webber K, Pezzella G, Jensen-Wachspress M, Lang H, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40032074
Chimeric antigen receptor-modified T (CAR-T) cell therapies are gaining wider use in relapsed and refractory malignancies. However, data on vaccination in this population is lacking. We evaluated T cell responses...
2.
Liang E, Huang J, Portuguese A, Ortiz-Maldonado V, Albittar A, Wuliji N, et al.
Blood Adv
. 2024 Dec;
9(3):606-616.
PMID: 39626349
Immune effector cell-associated hematotoxicity (ICAHT) is associated with morbidity and mortality after chimeric antigen receptor (CAR) T-cell therapy. To date, the factors associated with ICAHT are poorly characterized, and there...
3.
Liu W, Kampouri E, Bui J, Sekhon M, Tercero A, Finlay D, et al.
Mol Ther Methods Clin Dev
. 2024 Dec;
32(4):101361.
PMID: 39624798
Low levels and function of natural killer (NK) cells are associated with increased coronavirus disease 2019 (COVID-19) severity. NK cell immunotherapy may improve immune function to reduce infection severity. We...
4.
Sutherland N, Zhou B, Zhang L, Ong M, Hong J, Pak A, et al.
J Allergy Clin Immunol
. 2024 Nov;
155(2):605-615.
PMID: 39505278
Background: CD19-targeted chimeric antigen receptor T-cell therapy (CAR-T therapy) has revolutionized the treatment of hematologic malignancies. As these cells target CD19 receptors on B cells, there is the potential for...
5.
Kampouri E, Reynolds G, Teh B, Hill J
Curr Opin Infect Dis
. 2024 Oct;
37(6):526-535.
PMID: 39361275
Purpose Of Review: Infections are the leading cause of non-relapse mortality following chimeric antigen receptor (CAR)-T-cell therapy, with viral infections being frequent both in the early and late phases post-infusion....
6.
Stathis C, Zhu H, Carlin K, Phan T, Toomey D, Hill J, et al.
Bone Marrow Transplant
. 2024 Sep;
59(12):1683-1693.
PMID: 39245683
Human herpesvirus-6B (HHV-6B) reactivation has been associated with non-relapse mortality (NRM) and overall mortality (OM) following allogeneic hematopoietic stem cell transplant (HCT). We performed a systematic review and meta-analysis to...
7.
Rosen E, Krantz E, McCulloch D, Wilson M, Tverdek F, Kassamali Escobar Z, et al.
Transplant Cell Ther
. 2024 Aug;
30(11):1108.e1-1108.e11.
PMID: 39179107
Recipients of cellular therapies, including hematopoietic cell transplant (HCT) and chimeric antigen receptor T-cell (CART) therapy, are at risk for poor outcomes from coronavirus disease 2019 (COVID-19). There are limited...
8.
Madut D, Chemaly R, Dadwal S, Hill J, Lee Y, Haidar G, et al.
Open Forum Infect Dis
. 2024 Aug;
11(8):ofae425.
PMID: 39091643
Background: Plasma microbial cell-free DNA (mcfDNA) sequencing can establish the etiology of multiple infectious syndromes by identifying microbial DNA in plasma. However, data are needed to define the clinical scenarios...
9.
Shahid Z, Jain T, Dioverti V, Pennisi M, Mikkilineni L, Thiruvengadam S, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):955-969.
PMID: 39084261
Chimeric antigen receptor (CAR) T-cell therapy is rapidly advancing, offering promising treatments for patients with hematological malignancy. However, associated infectious complications remain a significant concern because of their contribution to...
10.
Zamora D, Xie H, Sadowska-Klasa A, Kampouri E, Biernacki M, Ueda Oshima M, et al.
Blood Adv
. 2024 Jun;
8(17):4568-4580.
PMID: 38924728
Cytomegalovirus (CMV) disease occurs occasionally before allogeneic hematopoietic cell transplantation (HCT) and is associated with poor post-HCT outcomes; however, the impact of pre-HCT CMV reactivation is unknown. Pre-HCT CMV reactivation...